Advertisement

International Journal of Hematology

, Volume 82, Issue 5, pp 389–396 | Cite as

Biology of Normal and Acute Myeloid Leukemia Stem Cells

Article

Abstract

The substantial understanding that has been gained over the past 5 decades of the biology of blood formation is largely due to the development of functional quantitative assays for cells at all stages of differentiation, from multipotential stem cells to mature cells. The majority of studies have involved the mouse because the ease with which repopulation studies can be carried out with this animal model allows the assay of complete lineage development from stem cells. In the past decade, advances in repopulation assays for human stem cells using xenotransplantation have greatly enhanced our understanding of human stem cell biology. Importantly, the xenotransplantation methodology has also been used to identify the cancer stem cell that initiates and sustains leukemic proliferation, providing key evidence for the cancer stem cell hypothesis. This hypothesis argues that cancer cells are functionally heterogeneous and hierarchically organized such that only specific cells are capable of sustaining tumor growth and continuously producing the cells that make up the bulk of the tumor. Recent studies have also brought into focus the importance of the intimate relationship between the stem cell (normal or leukemic) and its microenvironment. Coming into view are the molecular players involved in stem cell homing, migration, and adhesion, as well as the cellular components of the microenvironmental niche. Here we review recent studies that have begun to elucidate the interplay between normal and leukemic human stem cells and their microenvironment.

Key words

Cancer stem cells NOD/SCID Xenotransplantation Cancer Leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rawlings DJ, Quan S, Hao QL. Differentiation of human CD34+CD38- cord blood stem cells into B cell progenitors in vitro. Exp Hematol. 1997;25:66–72.PubMedGoogle Scholar
  2. 2.
    Hao QL, Smogorzewska EM, Barsky LW, Crooks GM. In vitro identification of single CD34+CD38- cells with both lymphoid and myeloid potential. Blood. 1998;91:4145–4151.PubMedGoogle Scholar
  3. 3.
    Gan OI, Dorell C, Pereira DS, Ito CY, Wang JC, Dick JE. Characterization and retroviral transduction of an early human lymphomyeloid precursor assayed in nonswitched long-term culture on murine stroma. Exp Hematol. 1999;27:1097–1106.CrossRefPubMedGoogle Scholar
  4. 4.
    Nakauchi H, Sudo K, Ema H. Quantitative assessment of the stem cell self-renewal capacity. Ann N Y Acad Sci. 2001;938:18–24, discussion 24–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Ema H, Takano H, Sudo K, Nakauchi H. In vitro self-renewal division of hematopoietic stem cells. J Exp Med. 2000;192:1281–1288.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ema H, Sudo K, Seita J, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev Cell. 2005;8:907–914.CrossRefPubMedGoogle Scholar
  7. 7.
    Adolfsson J, Mansson R, Buza-Vidas N, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential: a revised road map for adult blood lineage commitment. Cell. 2005;121:295–306.CrossRefGoogle Scholar
  8. 8.
    Akashi K, Traver D, Zon LI. The complex cartography of stem cell commitment. Cell. 2005;121:160–162.CrossRefPubMedGoogle Scholar
  9. 9.
    Dick JE. Stem cells: self-renewal writ in blood. Nature. 2003;423:231–233.CrossRefPubMedGoogle Scholar
  10. 10.
    Lessard J, Faubert A, Sauvageau G. Genetic programs regulating HSC specification, maintenance and expansion. Oncogene. 2004;23:7199–7209.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoang T. The origin of hematopoietic cell type diversity. Oncogene. 2004;23:7188–7198.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang JC, Dorrell C, Ito CY, et al. Normal and leukemic human stem cells assayed in immune-deficient mice. In: Zon LI, ed. Hematopoiesis: A Developmental Approach. New York, NY: Oxford University Press; 2001:99–118.Google Scholar
  13. 13.
    Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene. 2004;23:7164–7177.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood. 1997;89:3919–3924.PubMedGoogle Scholar
  15. 15.
    Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc NatlAcad Sci USA. 1997;94:9836–9841.CrossRefGoogle Scholar
  16. 16.
    Larochelle A, Vormoor J, Hanenberg H, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med. 1996;2:1329–1337.CrossRefPubMedGoogle Scholar
  17. 17.
    Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science. 1992;255:1137–1141.CrossRefPubMedGoogle Scholar
  18. 18.
    Guenechea G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol. 2001;2:75–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Lemischka IR, Jordan CT. The return of clonal marking sheds new light on human hematopoietic stem cells. Nat Immunol. 2001;2:11–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim HJ, Tisdale JF, Wu T, et al. Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in non- human primates. Blood. 2000;96:1–8.PubMedGoogle Scholar
  21. 21.
    Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lym- phohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 1996;273:242–245.CrossRefPubMedGoogle Scholar
  22. 22.
    Benveniste P, Cantin C, Hyam D, Iscove N. Hematopoietic stem cells engraft in mice with absolute efficiency. Nat Immunol. 2003;4:708–713.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu H, Verfaillie CM. Myeloid-lymphoid initiating cells (ML-IC) are highly enriched in the rhodamine-c-kit+CD33-CD38- fraction of umbilical cord CD34+ cells. Exp Hematol. 2002;30:582–589.CrossRefPubMedGoogle Scholar
  24. 24.
    Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA. 1997;94:5320–5325.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol. 1998;26:353–360.PubMedGoogle Scholar
  26. 26.
    Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 1998;4:1038–1045.CrossRefPubMedGoogle Scholar
  27. 27.
    Ando K, Nakamura Y, Chargui J, et al. Extensive generation of human cord blood CD34+ stem cells from Lin-CD34- cells in a long-term in vitro system. Exp Hematol. 2000;28:690–699.CrossRefPubMedGoogle Scholar
  28. 28.
    Cashman JD, Eaves CJ. High marrow seeding efficiency of human lymphomyeloid repopulating cells in irradiated NOD/SCID mice. Blood. 2000;96:3979–3981.PubMedGoogle Scholar
  29. 29.
    van Hennik PB, de Koning AE, Ploemacher RE. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/ severe combined immune deficiency mice: implications for stem cell frequency assessment. Blood. 1999;94:3055–3061.PubMedGoogle Scholar
  30. 30.
    Glimm H, Eisterer W, Lee K, et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin-null mice. J Clin Invest. 2001;107:199–206.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci USA. 2002;99:413–418.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kerre TC, De Smet G, De Smedt M, et al. Both CD34+38+ and CD34+38- cells home specifically to the bone marrow of NOD/ LtSZ scid/scid mice but show different kinetics in expansion. J Immunol. 2001;167:3692–3698.CrossRefPubMedGoogle Scholar
  33. 33.
    McKenzie JL, Gan OI, Doedens M, Dick JE. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood. 2005;106:1259–1261.CrossRefPubMedGoogle Scholar
  34. 34.
    Wang L, Menendez P, Shojaei F, et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med. 2005;201:1603–1614.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Yahata T, Ando K, Sato T, et al. A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow. Blood. 2003;101:2905–2913.CrossRefGoogle Scholar
  36. 36.
    Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med. 2003;9:959–963.CrossRefGoogle Scholar
  37. 37.
    Kollet O, Peled A, Byk T, et al. β2 Microglobulin-deficient (B2mnull) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood. 2000;95:3102–3105.Google Scholar
  38. 38.
    Ishikawa F, Livingston AG, Wingard JR, Nishikawa S, Ogawa M. An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/β2-microglobulinnull mice. Exp Hematol. 2002;30:488–494.CrossRefGoogle Scholar
  39. 39.
    Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004;304:104–107.CrossRefGoogle Scholar
  40. 40.
    Pflumio F, Lapidot T, Murdoch B, Patterson B, Dick JE. Engraft- ment of human lymphoid cells into newborn SCID mice leads to graft-versus-host disease. Int Immunol. 1993;5:1509–1522.CrossRefPubMedGoogle Scholar
  41. 41.
    Shultz LD, Banuelos SJ, Leif J, et al. Regulation of human shortterm repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122+ cells. Exp Hematol. 2003;31:551–558.CrossRefPubMedGoogle Scholar
  42. 42.
    Zanjani E, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M. Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol. 1998;26:353–360.PubMedGoogle Scholar
  43. 43.
    Nakamura Y, Ando K, Chargui J, et al. Ex vivo generation of CD34+ cells from CD34- hematopoietic cells. Blood. 1999;94:4053–4059.PubMedGoogle Scholar
  44. 44.
    Ito T, Tajima F, Ogawa M. Developmental changes of CD34 expres- sion by murine hematopoietic stem cells. Exp Hematol. 2000;28:1269–1273.CrossRefPubMedGoogle Scholar
  45. 45.
    Sato T, Laver JH, Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood. 1999;94:2548–2554.PubMedGoogle Scholar
  46. 46.
    Dao MA, Arevalo J, Nolta JA. Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for sec- ondary reconstitution. Blood. 2003;101:112–118.CrossRefPubMedGoogle Scholar
  47. 47.
    Okuno Y, Hettner CS, Radomska HS, et al. Distal elements are critical for human CD34 expression in vivo. Blood. 2002;100:4420–4426.CrossRefPubMedGoogle Scholar
  48. 48.
    Wang J, Kimura T, Asada R, et al. SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood. 2003;101:2924–2931.CrossRefPubMedGoogle Scholar
  49. 49.
    Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337–1345.CrossRefPubMedGoogle Scholar
  50. 50.
    Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15:494–501.CrossRefPubMedGoogle Scholar
  51. 51.
    Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648.CrossRefGoogle Scholar
  52. 52.
    Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737.CrossRefGoogle Scholar
  53. 53.
    Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature. 2003;423:455–460.CrossRefGoogle Scholar
  54. 54.
    Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111.CrossRefPubMedGoogle Scholar
  55. 55.
    Pereira DS, Dorrell C, Ito CY, et al. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. Proc NatlAcad Sci USA. 1998;95:8239–8244.CrossRefGoogle Scholar
  56. 56.
    Mulloy JC, Cammenga J, Berguido FJ, et al. Maintaining the self- renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 2003;102:4369–4376.CrossRefPubMedGoogle Scholar
  57. 57.
    Wang JC, Warner JK, Erdmann N, Lansdorp PM, Harrington L, Dick JE. Dissociation of telomerase activity and telomere length maintenance in primitive human hematopoietic cells. Proc Natl Acad Sci USA. 2005;102:14398–14403.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Warner JK, Wang JC, Takenaka K, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia. 2005;19:1794–1805.CrossRefPubMedGoogle Scholar
  59. 59.
    Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self- renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17:3029–3035.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Huntly BJ, Shigematsu H, Deguchi K. MOZ-TIF2, but not BCR- ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6:587–596.CrossRefPubMedGoogle Scholar
  61. 61.
    Passegue E, Wagner EF, Weissman IL. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004;119:431–443.CrossRefPubMedGoogle Scholar
  62. 62.
    Hope K, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738–743.CrossRefGoogle Scholar
  63. 63.
    Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002;99:16220–16225.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 2002;16:559–562.CrossRefPubMedGoogle Scholar
  65. 65.
    Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;105:1901–1910.CrossRefGoogle Scholar
  66. 66.
    Zipori D, Krupsky M, Resnitzky P. Stromal cell effects on clonal growth of tumors. Cancer. 1987;60:1757–1762.CrossRefPubMedGoogle Scholar
  67. 67.
    Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841–846.CrossRefPubMedGoogle Scholar
  68. 68.
    Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836–841.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431:997–1002.CrossRefPubMedGoogle Scholar
  70. 70.
    Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;115:545–553.CrossRefPubMedGoogle Scholar
  71. 71.
    Kamel-Reid S, Letarte M, Sirard C, et al. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science. 1989;246:1597–1600.CrossRefPubMedGoogle Scholar
  72. 72.
    Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64:2817–2824.CrossRefPubMedGoogle Scholar
  73. 73.
    Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106:1331–1339.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858–864.CrossRefPubMedGoogle Scholar
  75. 75.
    Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood. 2004;103:2981–2989.CrossRefPubMedGoogle Scholar
  76. 76.
    Konopleva M, Konoplev S, Hu W, Zaritsky AY, Afanasiev BV, Andreef M. Stromal cells prevent apoptosis of AML cells by up- regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713–1724.CrossRefPubMedGoogle Scholar
  77. 77.
    Bendall LJ, Daniel A, Kortlepel K, Gottlieb DJ. Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol. 1994;22:1252–1260.PubMedGoogle Scholar
  78. 78.
    Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158–1165.CrossRefPubMedGoogle Scholar
  79. 79.
    Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969–973.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Spiegel A, Kollet O, Peled A, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood. 2004;103:2900–2907.CrossRefPubMedGoogle Scholar
  81. 81.
    Petit I, Goichberg P, Spiegel A, et al. Atypical PKC-ζ regulates SDF-1-mediated migration and development of human CD34+ progenitor cells. J Clin Invest. 2005;115:168–176.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Tavor S, Petit I, Porozov S, et al. Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood. 2005;106:2120–2127.CrossRefPubMedGoogle Scholar
  83. 83.
    Jin L, Hope K, Smadja-Joffe F, Dick JE. Selective eradication of acute myeloid leukemia stem cells using an antibody that ligates the CD44 adhesion molecule [abstract]. Blood. 2003;102. Abstract 2291.Google Scholar
  84. 84.
    Charrad RS, Li Y, Delpech B, et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med. 1999;5:669–676.CrossRefPubMedGoogle Scholar
  85. 85.
    Fukuda S, Broxmeyer HE, Pelus LM. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-lα(CXCL12)/CXCR4 axis. Blood. 2005;105:3117–3126.CrossRefPubMedGoogle Scholar
  86. 86.
    Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104:550–557.CrossRefPubMedGoogle Scholar
  87. 87.
    Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw. 2003;14:149–153..PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  1. 1.Department of Molecular and Medical GeneticsUniversity of Toronto, and Division of Cell and Molecular Biology, University Health NetworkToronto, OntarioCanada
  2. 2.Department of ImmunologyWeizmann InstituteRehovotIsrael

Personalised recommendations